Skip to content
2000
Volume 5, Issue 3
  • ISSN: 1573-4021
  • E-ISSN: 1875-6506

Abstract

Diabetic retinopathy affects a significant proportion of people with diabetes. Epidemiological studies suggest that hypertension is related to diabetic retinopathy, and major clinical trials has provided clear evidence that controlling blood pressure in diabetic patients with hypertension reduces the incidence and progression of retinopathy and visual loss. The United Kingdom Prospective Diabetes Study (UKPDS) showed that a 10 mmHg reduction in systolic blood pressure is associated with a 10% reduction in the risk of retinopathy. However, the UKPDS suggest that adequate blood pressure control must be maintained over time for sustained benefits on retinopathy and other microvascular complications. Recent trials suggest that there is a limit to retinopathy risk reduction achievable through lowering blood pressure to near normal levels. Newer trials also provide initial evidence that specific inhibition of the renin angiotensin system (RAS), particularly with angiotensin II-receptor blockers (ARB), may have an additional protective effect against retinopathy. Early detection of retinopathy through comprehensive dilated eye examinations by eye care providers, controlling modifiable risk factors (glucose, blood pressure and lipids) and appropriate referral for treatment are the cornerstones in management of diabetic retinopathy in the community.

Loading

Article metrics loading...

/content/journals/chyr/10.2174/157340209788921158
2009-08-01
2025-11-01
Loading full text...

Full text loading...

/content/journals/chyr/10.2174/157340209788921158
Loading

  • Article Type:
    Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test